 Your new post is loading...
Your new post is loading...
Scoop.it!
Signaling through chemokine receptors triggers migration of transplanted neural precursor cells in MS model #oa http://t.co/8dtDpGEoc9 
No comment yet.
Sign up to comment
Scoop.it!
We have previously identified eight novel autoantibody targets in the cerebrospinal fluid of multiple sclerosis (MS) patients, including sperm-associated Ag 16 (SPAG16).
Scoop.it!
Original Article from The New England Journal of Medicine — B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis (@lodaox @MustStopMS #Rituximab reduced relapses in half in Phase II trial in #MS.
RESULTS As compared with patients who received placebo, patients who received rituximab had reduced counts of total gadolinium-enhancing lesions at weeks 12, 16, 20, and 24 (P<0.001) and of total new gadolinium-enhancing lesions over the same period (P<0.001); these results were sustained for 48 weeks (P<0.001). As compared with patients in the placebo group, the proportion of patients in the rituximab group with relapses was significantly reduced at week 24 (14.5% vs. 34.3%, P=0.02) and week 48 (20.3% vs. 40.0%, P=0.04). More patients in the rituximab group than in the placebo group had adverse events within 24 hours after the first infusion, most of which were mild-to-moderate events; after the second infusion, the numbers of events were similar in the two groups. Full Text of Results... CONCLUSIONS A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of B-cell involvement in the pathophysiology of relapsing–remitting multiple sclerosis. (ClinicalTrials.gov number,NCT00097188.) Via Krishan Maggon
Scoop.it!
Is the gut microbiome a potential cause and therapeutic target for autoimmune ...
Scoop.it!
PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Scoop.it!
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Reduces Relapses, Disability Progression and Brain Lesions with a Favorable Safety Profile − − Only Pegylated Interferon in MS, Dosed Once Every Two Weeks – − Complements Biogen Idec’s Industry-Leading Portfolio of MS Products – CAMBRIDGE, Mass.Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). PLEGRIDY, the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe.
The FDA approval of PLEGRIDY is based on results from one of the largest pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients. ADVANCE was a two-year, Phase 3, placebo-controlled (in year one) study that evaluated the efficacy and safety of PLEGRIDY administered subcutaneously. The analysis for all primary and secondary efficacy endpoints occurred at the end of year one. After the first year, patients on placebo received PLEGRIDY for the duration of the study. In the first year of the ADVANCE clinical trial, PLEGRIDY dosed once every two weeks significantly reduced annualized relapse rate (ARR) at one year by 36 percent compared to placebo (p=0.0007). PLEGRIDY reduced the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale, by 38 percent (p=0.0383) compared to placebo. PLEGRIDY also significantly reduced the number of new gadolinium-enhancing [Gd+] lesions by 86 percent (p<0.0001) and reduced new or newly enlarging T2-hyperintense lesions by 67 percent (p<0.0001) compared to placebo.
The most common adverse reactions were injection site reaction, flu-like illness, fever, headache, muscle pain, chills, injection site pain, weakness, injection site itching and joint pain. The ADVANCE two-year safety data were consistent with safety results observed in year one. Via Krishan Maggon
Krishan Maggon 's curator insight,
August 15, 2014 8:39 PM
About PLEGRIDY™ PLEGRIDY was approved by EMA/EC this year. PLEGRIDY is a new subcutaneous injectable therapy indicated for relapsing forms of MS, in which interferon beta-1a is pegylated to extend its half-life to permit a less frequent dosing schedule. PLEGRIDY is a member of the interferon class of treatments for MS. Clinical and MRI data from the ADVANCE study of PLEGRIDY demonstrated a reduction in relapses, disability progression and the number of MS lesions when compared to placebo, and further support its clinical efficacy profile. The safety and tolerability profile of PLEGRIDY observed in ADVANCE was consistent with that of established MS interferon therapies. The recommended dosage of PLEGRIDY is 125 micrograms injected subcutaneously every 14 days. Patients should start treatment with 63 micrograms on day one. On day 15, the dose is increased to 94 micrograms, reaching the full dose of 125 micrograms on day 29. Severe hepatic injury, including hepatitis, autoimmune hepatitis, and rare cases of severe hepatic failure have been reported with interferon beta. Elevations in hepatic enzymes and hepatic injury have been observed with the use of PLEGRIDY in clinical studies. Depression, suicidal ideation and suicide have been reported in patients receiving interferon beta. Seizures are also associated with the use of interferon beta. Anaphylaxis and other serious allergic reactions are rare complications of treatment with interferon beta. Injection site reactions, including injection site necrosis, can occur with the use of subcutaneous interferon beta. Congestive heart failure, cardiomyopathy and cardiomyopathy with congestive heart failure occur in patients receiving interferon beta. Interferon beta can cause decreased peripheral blood counts in all cell lines, including rare instances of pancytopenia and severe thrombocytopenia. Autoimmune disorders of multiple target organs including idiopathic thrombocytopenia, hyper and hypothyroidism, and autoimmune hepatitis have been reported with interferon beta.
Scoop.it!
"More on B cells. For those of you who are not immunologists the following paper will be seem confusing. B cells are the types of lymphocyte that mature to make antibodies. When they are naive, i.e. have not participated in a ...
Scoop.it!
by Pia Kivisäkk, Katiana Francois, Julvet Mbianda, Roopali Gandhi, Howard L. Weiner, Samia J. Khoury
Scoop.it!
by Suzanne Speck, James Lim, Sagar Shelake, Marsel Matka, Jonathan Stoddard, Alexander Farr, Vijay Kuchroo, Yasmina Laouar While the role of Transforming Growth Factor β (TGF-β) as an intrinsic pathway has been well established in driving de novo...
Scoop.it!
In-depth characterization of the cerebrospinal fluid proteome displayed through the CSF Proteome Resource (CSF-PR). http://t.co/38mZGJ8HhF
Gilbert C FAURE's insight:
full text preprint A maximal protein
Scoop.it!
Fluids and Barriers of the CNS 2014, 11:10 According to the traditional understanding of cerebrosspinal fluid (CSF) physiology, the majority of CSF is produced by the choroid plexus, circulates thr...
Scoop.it!
NYSCF scientists one step closer to cell therapy for multiple sclerosis patients EurekAlert (press release) NEW YORK, NY (July 24, 2014) – Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a...
|
Scoop.it!
Plasma biosignature and brain pathology related to persistent cognitive ...
Scoop.it!
The final program of the 9th ISNIM Congress
Scoop.it!
Novus Light Technologies Today 3D Imaging Method Sheds Light on Neuroinflammatory Diseases Novus Light Technologies Today “Owing to the increased tortuosity of the choroid plexus capillaries and the underlying epithelial layer, information acquired...
Scoop.it!
PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.
Scoop.it!
Secondary autoimmunity occurs in ~50% of MSers treated with alemtuzumab. #ClinicSpeak #MSBlog #MSResearch http://t.co/QNUpF0gUx0 Via Krishan Maggon
Krishan Maggon 's curator insight,
August 17, 2014 11:08 AM
Tuohy et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2014 May 21. pii: jnnp-2014-307721. doi: 10.1136/jnnp-2014-307721. CONCLUSIONS: Alemtuzumab is associated with disease stabilisation in the majority of MSers with highly active RRMS over an average seven-year follow-up. No new safety concerns arose over this extended follow-up.
Scoop.it!
Preliminary Final Report for the Year Ended 30 June 2014
Scoop.it!
The immunomodulatory effects of human mesenchymal #stemcells on peripheral blood mononuclear cells in ALS patients http://t.co/qDst1OjYkJ
Claire Dubois's curator insight,
December 7, 2022 4:32 AM
c’est un article extrement enrichissant et interessant mais assez complexe à comprendre entre le vocabulaire, les abréviations, les schémas …
Scoop.it!
Rajbhandari L, Tegenge MA, Shrestha S, Ganesh Kumar N, Malik A, Mithal A, Hosmane S, Venkatesan A. Toll-like receptor 4 deficiency impairs microglial phagocytosis of degenerating axons. Glia. 2014 Jul 8.
Scoop.it!
Cytokine pathway disruption in a mouse model of schizophrenia induced by Munc18-1a overexpression in the brain - up-to-the-minute news and headlines. Via Société Francaise d'Immunologie
Scoop.it!
Disruption of the blood-brain and blood-spinal cord barriers (BBB and BSCB, respectively) and immune cell infiltration are early pathophysiological hallmarks of multiple sclerosis (MS), its animal model experimental ...
Scoop.it!
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. By - Prof Michael Weller MD, Prof Martin van den Bent MD, Kirsten Hopkins MD, Prof Jörg C Tonn MD, Prof Roger ...
Scoop.it!
Network of experts join forces to fight rare disease Cordis News Sara Fuchs, professor of neuro-immunology at the Weizmann Institute of Science, Rehovot, Israel, also believes monocloncal antibody therapy is “a very promising approach.” She tells...
|
